Last updated July 18, 2026
Key finding
Adjusted mean reduction in HbA1c was statistically significant, changing from 8.76% to 6.97% (p < 0.001).
This study evaluated the efficacy and safety of dapagliflozin combined with gliclazide in patients with Type 2 diabetes, finding significant reductions in HbA1c and fasting plasma glucose levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of dapagliflozin combined with gliclazide in patients with Type 2 diabetes, finding significant reductions in HbA1c and fasting plasma glucose levels.
These findings are clinically significant as they suggest that combining dapagliflozin with gliclazide may provide enhanced glycemic control for patients with Type 2 diabetes. Improved management of blood sugar levels can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.
The study did not assess long-term outcomes beyond the intervention period. Sample size may limit the generalizability of the findings. The variation in proportions achieving HbA1c < 8% was not statistically significant.
Published in
Publication details and source links for this paper.
Alexander M, John RA, Suhas GE, et al. Efficacy and Safety of Dapagliflozin and Gliclazide Combination in Type 2 Diabetes. Cureus. 2026;18(2):e103676. doi:10.7759/cureus.103676
Dapagliflozin and gliclazide combination reduced HbA1c from 8.76% to 6.97% (p < 0.001).
Fasting plasma glucose decreased by 52.72 mg/dl (p = 0.008) with the combination treatment.
Postprandial plasma glucose decreased by 74.75 mg/dl (p = 0.038) in the combination group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin, Dapagliflozin Gliclazide combination and Fasting Plasma Glucose (FPG), Glucose iAUC (OGTT), HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
8
Evidence pairs
584
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Dapagliflozin → Fasting Plasma Glucose (FPG)
Dapagliflozin → Fasting Plasma Glucose (FPG)
Dapagliflozin → Percentage of hypoglycemic events
Dapagliflozin → Percentage of hypoglycemic events
Dapagliflozin Gliclazide combination → Fasting Plasma Glucose (FPG)
Dapagliflozin Gliclazide combination → Fasting Plasma Glucose (FPG)
Dapagliflozin Gliclazide combination → Glucose iAUC (OGTT)
Dapagliflozin Gliclazide combination → Glucose iAUC (OGTT)
Dapagliflozin Gliclazide combination → Percentage of hypoglycemic events
Dapagliflozin Gliclazide combination → Percentage of hypoglycemic events
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
6 results
3 results
6 results
6 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 77.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
Dapagliflozin Gliclazide combination appears to improve Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
